Identification of DNA methylation signatures associated with poor outcome in lower-risk Stage, Size, Grade and Necrosis (SSIGN) score clear cell renal cell cancer

Louis Y. El Khoury, Shuang Fu, Ryan A. Hlady, Ryan T. Wagner, Liguo Wang, Jeanette E. Eckel-Passow, Erik P. Castle, Melissa L. Stanton, R. Houston Thompson, Alexander S. Parker, Thai H. Ho, Keith D. Robertson

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Despite using prognostic algorithms and standard surveillance guidelines, 17% of patients initially diagnosed with low risk clear cell renal cell carcinoma (ccRCC) ultimately relapse and die of recurrent disease, indicating additional molecular parameters are needed for improved prognosis. Results: To address the gap in ccRCC prognostication in the lower risk population, we performed a genome-wide analysis for methylation signatures capable of distinguishing recurrent and non-recurrent ccRCCs within the subgroup classified as ‘low risk’ by the Mayo Clinic Stage, Size, Grade, and Necrosis score (SSIGN 0–3). This approach revealed that recurrent patients have globally hypermethylated tumors and differ in methylation significantly at 5929 CpGs. Differentially methylated CpGs (DMCpGs) were enriched in regulatory regions and genes modulating cell growth and invasion. A subset of DMCpGs stratified low SSIGN groups into high and low risk of recurrence in independent data sets, indicating that DNA methylation enhances the prognostic power of the SSIGN score. Conclusions: This study reports a global DNA hypermethylation in tumors of recurrent ccRCC patients. Furthermore, DMCpGs were capable of discriminating between aggressive and less aggressive tumors, in addition to SSIGN score. Therefore, DNA methylation presents itself as a potentially strong biomarker to further improve prognostic power in patients with low risk SSIGN score (0–3).

Original languageEnglish (US)
Article number12
JournalClinical Epigenetics
Volume13
Issue number1
DOIs
StatePublished - Dec 2021

Keywords

  • DNA methylation
  • Epigenetics
  • Kidney cancer
  • Precision medicine
  • Prognostic marker
  • Reduced representation bisulfite sequencing (RRBS)
  • SSIGN score
  • ccRCC

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Developmental Biology
  • Genetics(clinical)

Fingerprint Dive into the research topics of 'Identification of DNA methylation signatures associated with poor outcome in lower-risk Stage, Size, Grade and Necrosis (SSIGN) score clear cell renal cell cancer'. Together they form a unique fingerprint.

Cite this